FY 2020  
Anti-Heroin Task Force (AHTF) Program  
Section 13 Attachment

Agencies that seek funding under this program are required to submit a project narrative. To do so, please develop one narrative that provides responses to the following six questions. The project narrative portion of the application is limited to 8 pages (maximum, double spaced, 12-point font). Please note that if the project narrative exceeds the page limit, the peer reviewers will not review beyond the page limit requirement, so narratives should be as clear and concise as possible; and the bulk of the narrative should focus on the proposed project (question 5). Submit this narrative as an attachment under section 13 of the application.

Project narrative

1. Using the most current and accurate information available, please describe your jurisdiction’s heroin, fentanyl, or carfentanil or unlawful distribution of prescription opioids threat(s) that will be addressed with this grant and provide relevant facts, statistics, or other supporting information that documents the nature, prevalence, and severity of the problem (including rates of primary treatment admission for heroin, fentanyl, carfentanil, and other opioids). A comprehensive narrative (illustrated with charts, graphs, tables, or other visual tools) should be developed that accurately and concisely describes

   A. the extent of the threat;
   B. the significance of prescription drug diversion in the jurisdiction, noting, where known, the most frequently diverted substance (e.g., OxyContin, Vicodin);
   C. if possible, the relative significance of pharmacy burglaries and robberies, doctor shopping, pill mills, prescription fraud, and internet sales;
   D. if the jurisdiction is a source of prescription drugs for other parts of the country.

2. Please describe your jurisdiction’s current investigative activities used to locate or investigate illicit activities relating to the distribution of heroin, fentanyl, or carfentanil or the unlawful distribution of prescription opioids.

3. Does your agency currently participate in an anti-heroin and other opioids task force?

   A. If yes, please describe the following:

      a) The task force name, structure, responsibilities, when the task force was created, and the populations and jurisdictions served
      b) The number and type (s) of agencies that participate in the task force (include the total number of full-time equivalents (FTE) (sworn and civilian) assigned to the task force)
c) Your agency’s and partner agencies’ roles in the task force (include the specific contributions provided to the task force and the number of FTEs (sworn and civilian) allocated to the task force)

d) Is the task force part of a High Intensity Drug Trafficking Area (HIDTA)? If yes, please provide the name of the HIDTA and the task force commander and describe your agency’s experience in working with the task force

e) Any additional information that will assist us in understanding your agency’s participation in the task force

B. If your agency is not currently part of a task force, please describe the following:

   a) The proposed task force name, its structure and responsibilities, and the populations and jurisdictions to be served
   b) The proposed number and type(s) of agencies that will participate in the task force (include the total number of FTEs (sworn and civilian) that will be assigned to the task force)
   c) Your agency’s proposed role in the task force (include the specific contributions that your agency will provide to the task force and the number of FTEs (sworn and civilian) that your agency will allocate to the task force)
   d) Any additional information that will assist us in understanding your proposed plan to develop a task force and your agency’s proposed participation in the task force

4. Has your jurisdiction had a HIDTA threat assessment? If so, please provide a summary of the assessment with regard to heroin, fentanyl, carfentanil, and other opioids.

5. Please describe your agency’s proposed AHTF project by responding to the following:

   A. Identify the goals that your agency is ultimately trying to accomplish through federal assistance and how the proposed project would fit into an overall effort to address the distribution of heroin, fentanyl, or carfentanil or unlawful distribution of prescription opioids.
   B. How will funding, if awarded, be used to enhance your agency’s current anti-heroin and other opioids investigative activities?
   C. How will your agency ensure effective implementation of the project? Include a brief timeline with a list of key activities and milestones to take place within the life of the grant funding period. Activities may be grouped by month, quarter, or other format at the applicant’s discretion.
   D. How does your agency plan to determine the effectiveness of the project in meeting the program goals identified in question 5A? What strategies will be developed for measuring outcomes or progress towards program goals and objectives? List the outcomes and explain how they will be tracked, measured, and utilized.
   E. How will your agency employ a multidisciplinary approach to combatting your jurisdiction’s heroin and other opioids threat? Please include a description of collaborative efforts with the public health community on prevention, data-sharing, treatment, and recovery efforts. Please
include the proposed disciplines and/or entities involved and the extent/level of their engagement.

F. How will your agency coordinate with federal, state, local and tribal law enforcement agencies to maximize the impact and effectiveness of the project? How will your agency coordinate with the U.S. Attorney’s Office in your state? How will your agency coordinate and work with local and tribal law enforcement agencies in areas impacted by the project? How will your agency coordinate with other federal law enforcement partners such as the Federal Bureau of Investigation (FBI) or Drug Enforcement Administration (DEA) to assist tribal law enforcement agencies?

G. How will your agency make use of existing intelligence sharing resources within your jurisdiction including Fusion Centers, Regional Information Sharing Systems (RISS), etc.?

6. Does your agency have previous AHTF awards? If so, please explain the following:

   a) The status of the previous awards (have the awards been fully implemented?)
   b) Will this new AHTF request enhance any previous AHTF awards, or is this a new project?
   c) How have the previous AHTF awards affected your jurisdiction’s heroin/opioid challenges?

7. Data: Please provide your state’s rates per 100,000 population of primary treatment admissions for heroin, fentanyl, carfentanil, and other opioids.

<table>
<thead>
<tr>
<th>Rates per 100,000 population of primary treatment admissions for heroin</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rates per 100,000 population of primary treatment admissions for fentanyl</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rates per 100,000 population of primary treatment admissions for carfentanil</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rates per 100,000 population primary treatment admissions for other opioids</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>